Structure Therapeutics (NASDAQ:GPCR) Stock Price Down 6.1% – Should You Sell?

Structure Therapeutics Inc. (NASDAQ:GPCR) shares fell 6.1% on Thursday . The stock traded as low as $21.30 and last traded at $21.20. 227,654 shares changed hands during trading, a decline of 73% from the average session volume of 837,960 shares. The stock had previously closed at $22.57.

Analyst Ratings Changes

GPCR has been the topic of several recent analyst reports. HC Wainwright restated a “buy” rating and issued a $80.00 target price on shares of Structure Therapeutics in a report on Thursday, December 19th. Stifel Nicolaus started coverage on Structure Therapeutics in a research note on Wednesday, January 8th. They issued a “buy” rating and a $50.00 price objective on the stock. William Blair started coverage on Structure Therapeutics in a research report on Friday, February 28th. They set an “outperform” rating on the stock. Finally, JMP Securities reiterated a “market outperform” rating and issued a $91.00 target price on shares of Structure Therapeutics in a report on Wednesday, December 18th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, Structure Therapeutics has a consensus rating of “Buy” and a consensus target price of $81.29.

Structure Therapeutics Trading Down 4.1 %

The business has a 50-day moving average of $24.80 and a 200 day moving average of $31.84. The firm has a market capitalization of $1.20 billion, a P/E ratio of -28.34 and a beta of -2.37.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.01. As a group, research analysts forecast that Structure Therapeutics Inc. will post -0.82 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Geode Capital Management LLC increased its position in shares of Structure Therapeutics by 0.7% during the third quarter. Geode Capital Management LLC now owns 45,225 shares of the company’s stock worth $1,985,000 after acquiring an additional 312 shares in the last quarter. Virtus ETF Advisers LLC increased its holdings in Structure Therapeutics by 25.5% during the 4th quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company’s stock worth $61,000 after purchasing an additional 455 shares in the last quarter. ANTIPODES PARTNERS Ltd raised its stake in shares of Structure Therapeutics by 115.0% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company’s stock worth $28,000 after purchasing an additional 553 shares during the last quarter. LPL Financial LLC lifted its holdings in shares of Structure Therapeutics by 6.0% in the fourth quarter. LPL Financial LLC now owns 11,485 shares of the company’s stock valued at $311,000 after purchasing an additional 646 shares in the last quarter. Finally, Envestnet Asset Management Inc. boosted its position in shares of Structure Therapeutics by 12.9% during the fourth quarter. Envestnet Asset Management Inc. now owns 7,403 shares of the company’s stock valued at $201,000 after buying an additional 843 shares during the last quarter. 91.78% of the stock is owned by institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.